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(57) ABSTRACT 
Microneedle devices are provided for transport of molecules 
across tissue barriers and for use as microflameholders. In a 
preferred embodiment for transport across tissue, the micron-
eedles are formed of a biodegradable polymer. Methods of 
making these devices, which can include hollow and/or 
porous microneedles, are also provided. A preferred method 
for making a microneedle includes forming a micromold 
having sidewalls which define the outer surface of the micron-
eedle, electroplating the sidewalls to form the hollow micron-
eedle, and then removing the micromold from the micron-
eedle. In a preferred method of use, the microneedle device is 
used to deliver material into or across a biological barrier 
from chambers in connection with at least one of the micron-
eedles. The device preferably further includes a means for 
controlling the flow of material through the microneedles. 
Representative examples of these means include the use of 
permeable membranes, fracturable impermeable mem-
branes, valves, and pumps. 
20 Claims, 7 Drawing Sheets 
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MICRO NEEDLE DEVICES AND METHODS 
OF MANUFACTURE AND USE THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation of U.S. patent applica-
tion Ser. No. 12/150,945 filed on May 1, 2008 which is a 
continuation of U.S. patent application Ser. No. 10/010,723 
filed on Dec. 6, 2001, now abandoned which is a continuation 
of U.S. patent application Ser. No. 09/316,229 filed on May 
21, 1999, now U.S. Pat. No. 6,334,856, which is a continua-
tion-in-part ofU.S. Pat. No. 9,095,221, filed on Jun. 10, 1998, 
now U.S. Pat. No. 6,503,231. The entire contents of each of 
the above-referenced applications are hereby fully incorpo-
rated herein by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
The government has certain rights in this invention by 
virtue of Grant Number BES-9813321 awarded by the U.S. 
National Science Foundation to Mark R. Prausnitz, and sup-
port from the Defense Advanced Research Projects Agency 
(DARPA) to Mark G. Allen. 
BACKGROUND OF THE INVENTION 
This invention is generally in the field of devices for the 
transport of therapeutic or biological molecules across tissue 
barriers, such as for drug delivery. 
Numerous drugs and therapeutic agents have been devel-
oped in the battle against disease and illness. However, a 
frequent limitation of these drugs is their delivery: how to 
transport drugs across biological barriers in the body (e.g., the 
skin, the oral mucosa, the blood-brain barrier), which nor-
mally do not transport drugs at rates that are therapeutically 
useful or optimal. 
Drugs are commonly administered orally as pills or cap-
sules. However, many drugs cannot be effectively delivered in 
this manner, due to degradation in the gastrointestinal tract 
and/or elimination by the liver. Moreover, some drugs cannot 
effectively diffuse across the intestinal mucosa. Patient com-
pliance may also be a problem, for example, in therapies 
requiring that pills be taken at particular intervals over a 
prolonged time. 
2 
heat to create a hole in the skin, which is inconvenient, expen-
sive, or undesirable for repeated 
An alternative delivery technique is the transdermal patch, 
which usually relies on diffusion of the drug across the skin. 
However, this method is not useful for many drugs, due to the 
poor permeability (i.e. effective barrier properties) of the 
skin. The rate of diffusion depends in part on the size and 
hydrophilicity of the drug molecules and the concentration 
gradient across the stratum corneum. Few drugs have the 
10 
necessary physiochemical properties to be effectively deliv-
ered through the skin by passive diffusion. Iontophoresis, 
electroporation, ultrasound, and heat (so-called active sys-
tems) have been used in an attempt to improve the rate of 
15 delivery. While providing varying degrees of enhancement, 
these techniques are not suitable for all types of drugs, failing 
to provide the desired level of delivery. In some cases, they are 
also painful and inconvenient or impractical for continuous 
controlled drug delivery over a period of hours or days. 
20 Attempts have been made to design alternative devices for 
active transfer of drugs, or analyte to be measured, through 
the skin. 
For example, U.S. Pat. No. 5,879,326 to Godshall et al. and 
PCT WO 96/37256 by Silicon Microdevices, Inc. disclose a 
25 transdermal drug delivery apparatus that includes a cutter 
portion having a plurality of microprotrusions, which have 
straight sidewalls, extending from a substrate that is in com-
munication with a drug reservoir. In operation, the micropro-
trusions penetrate the skin until limited by a stop region of the 
30 substrate and then are moved parallel to the skin to create 
incisions. Because the microprotrusions are dragged across 
the skin, the device creates a wound sufficiently large to be a 
site of infection. Channels in the substrate adjacent to the 
microprotrusions allow drug from the reservoir to now to the 
35 skin near the area disrupted by the microprotrusions. Merely 
creating a wound, rather than using a needle which conveys 
drug through an enclosed channel into the site of administra-
tion, also creates more variability in dosage. 
U.S. Pat. No. 5,250,023 to Lee et al. discloses a transder-
40 ma! drug delivery device, which includes a plurality of skin 
needles having a diameter in the range of 50 to 400 µm. The 
skin needles are supported in a water-swellable polymer sub-
strate through which a drug solution permeates to contact the 
surface of the skin. An electric current is applied to the device 
45 to open the pathways created by the skin needles, following 
their withdrawal from the skin upon swelling of the polymer 
substrate. 
PCT WO 93/177 54 by Gross et al. discloses another trans-
dermal drug delivery device that includes a housing having a 
50 liquid drug reservoir and a plurality of tubular elements for 
transporting liquid drug into the skin. The tubular elements 
may be in the form of hollow needles having inner diameters 
ofless than 1 mm and an outer diameter of 1.0 mm. 
Another common technique for delivering drugs across a 
biological barrier is the use of a needle, such as those used 
with standard syringes or catheters, to transport drugs across 
(through) the skin. While effective for this purpose, needles 
generally cause pain; local damage to the skin at the site of 
insertion; bleeding, which increases the risk of disease trans-
mission; and a wound sufficiently large to be a site of infec-
tion. The withdrawal of bodily fluids, such as for diagnostic 55 
purposes, using a conventional needle has these same disad-
vantages. Needle techniques also generally require adminis-
tration by one trained in its use. The needle technique also is 
undesirable for long term, controlled continuous drug deliv-
ery. 
While each of these devices has potential use, there 
remains a need for better drug delivery devices, which make 
smaller incisions, deliver drug with greater efficiency (greater 
drug delivery per quantity applied) and less variability of drug 
administration, and/or are easier to use. 
It is therefore an object of the present invention to provide 
60 a microneedle device for relatively painless, controlled, safe, 
convenient transdermal delivery of a variety of drugs. Similarly, current methods of sampling biological fluids 
are invasive and suffer from the same disadvantages. For 
example, needles are not preferred for frequent routine use, 
such as sampling of a diabetic' s blood glucose or delivery of 
insulin, due to the vascular damage caused by repeated punc- 65 
tures. No alternative methodologies are currently in use. Pro-
posed alternatives to the needle require the use of lasers or 
It is another object of the present invention to provide a 
microneedle device for controlled sampling of biological flu-
ids in a minimally-invasive, painless, and convenient marmer. 
It is still another object of the present invention to provide 
a hollow microneedle array for use in delivery or sensing of 
drugs or biological fluids or molecules. 
US 8, 708,966 B2 
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SUMMARY OF THE INVENTION 
Microneedle devices for transport of molecules, including 
drugs and biological molecules, across tissue, and methods 
for manufacturing the devices, are provided. The microneedle 
devices permit drug delivery or removal of body fluids at 
clinically relevant rates across skin or other tissue barriers, 
with minimal or no damage, pain, or irritation to the tissue. 
Microneedles can be formed of biodegradable or non-biode-
gradable polymeric materials or metals. In a preferred 
embodiment, the microneedles are formed of a biodegradable 
polymer. In another preferred embodiment, the device 
includes a means for temporarily securing the microneedle 
device to the biological barrier to facilitate transport. 
Methods are provided for making porous or hollow 
microneedles. A preferred method for making a microneedle 
includes forming a micromold having sidewalls which define 
the outer surface of the microneedle. The micromold can be 
formed, for example, by photolithographically defining one 
or more holes in a substrate, or by laser based cutting (either 
serially or by using lithographic projection), or by using a 
mold-insert. In a preferred embodiment, the method includes 
electroplating the sidewalls to form the hollow microneedle, 
and then removing the micromold from the microneedle. 
4 
(e.g., oral, nasal, ocular, vaginal, urethral, gastrointestinal, 
respiratory); blood vessels; lymphatic vessels; or cell mem-
branes (e.g., for the introduction of material into the interior 
of a cell or cells). The biological barriers can be in humans or 
other types of animals, as well as in plants, insects, or other 
organisms, including bacteria, yeast, fungi, and embryos. 
The microneedle devices can be applied to tissue internally 
with the aid of a catheter or laparoscope. For certain applica-
tions, such as for drug delivery to an internal tissue, the 
10 devices can be surgically implanted. 
The microneedle device disclosed herein is typically 
applied to skin. The stratum corneum is the outer layer, gen-
erally between 10 and 50 cells, or between 10 and 20 µm 
thick. Unlike other tissue in the body, the stratum corneum 
15 contains "cells" (called keratinocytes) filled with bundles of 
cross-linked keratin and keratohyalin surrounded by an extra-
cellular matrix oflipids. It is this structure that is believed to 
give skin its barrier properties, which prevents therapeutic 
transdermal administration of many drugs. Below the stratum 
20 corneum is the viable epidermis, which is between 50 and 100 
µm thick. The viable epidermis contains no blood vessels, and 
it exchanges metabolites by diffusion to and from the dermis. 
Beneath the viable epidermis is the dermis, which is between 
1 and 3 mm thick and contains blood vessels, lymphatics, and 
25 nerves. The microneedle device is useful for delivery of fluid mate-
rial into or across a biological barrier wherein the fluid mate-
rial is delivered from one or more chambers in fluid connec-
tion with at least one of the microneedles. The device 
preferably further includes a means for controlling the flow of 
material through the microneedles. Representative examples 30 
of these means include the use of permeable membranes, 
fracturable impermeable membranes, valves, and pumps, and 
electrical means. 
2. The Microneedle Device 
The microneedle devices disclosed herein include a sub-
strate; one or more microneedles; and, optionally, a reservoir 
for delivery of drugs or collection of analyte, as well as 
pump(s), sensor(s), and/or microprocessor(s) to control the 
interaction of the foregoing. 
a. Substrate 
The substrate of the device can be constructed from a 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. la is a side elevational view of a preferred embodi-
ment of the microneedle device inserted into human skin. 
FIG. lb is a diagram of one embodiment of microneedles. 
variety of materials, including metals, ceramics, semiconduc-
35 tors, organics, polymers, and composites. The substrate 
includes the base to which the microneedles are attached or 
integrally formed. A reservoir may also be attached to the 
substrate. 
b. Microneedle 
FIGS. 2a-e are side cross-sectional views of a method for 40 The microneedles of the device can be constructed from a 
variety of materials, including metals, ceramics, semiconduc-
tors, organics, polymers, and composites. Preferred materials 
of construction include pharmaceutical grade stainless steel, 
gold, titanium, nickel, iron, gold, tin, chromium, copper, 
alloys of these or other metals, silicon, silicon dioxide, and 
polymers. Representative biodegradable polymers include 
making microneedles. 
FIGS. 3a-g are side cross-sectional views of a method for 
making a hollow microneedle. 
FIGS. 4a through 4d are side cross-sectional views illus-
trating a preferred method for making hollow microneedles. 45 
FIGS. Sa through Sd are side cross-sectional views illus-
trating a preferred method for making hollow silicon micro-
tubes. 
FIGS. 6a through 6e are side cross-sectional views illus-
trating a preferred method for making hollow metal micro- 50 
tubes. 
FIGS. 7a through 7d are side cross-sectional views illus-
trating a preferred method for making tapered metal micron-
eedles. 
FIGS. Sa through Sd are side cross-sectional views illus- 55 
trating a method for making tapered microneedles using 
laser-formed molds. 
polymers of hydroxy acids such as lactic acid and glycolic 
acid polylactide, polyglycolide, polylactide-co-glycolide, 
and copolymers with PEG, polyanhydrides, poly( ortho )e-
sters, polyurethanes, poly(butyric acid), poly(valeric acid), 
and poly(lactide-co-caprolactone ). Representative non-bio-
degradable polymers include polycarbonate, poly-
methacrylic acid, ethylenevinyl acetate, polytetrafluoroac-
etate (TEFLON™), and polyesters. 
Generally, the microneedles should have the mechanical 
strength to remain intact for delivery of drugs, or serve as a 
conduit for the collection of biological fluid, while being 
inserted into the skin, while remaining in place for up to a 
number of days, and while being removed. In embodiments 
FIGS. 9a through 9/ are side cross-sectional views illus-
trating a second method for making tapered microneedles 
using laser-formed molds. 
DETAILED DESCRIPTION OF THE INVENTION 
1. Biological Barriers 
60 where the microneedles are formed of biodegradable poly-
mers, however, this mechanical requirement is less stringent, 
since the microneedles or tips thereof can break off, for 
example in the skin, and will biodegrade. Nonetheless, even a 
biodegradable microneedle still needs to remain intact at least 
The devices disclosed herein are useful in transport of 
material into or across biological barriers including the skin 
(or parts thereof); the blood-brain barrier; mucosa! tissue 
65 long enough for the microneedle to serve its intended purpose 
( e.g, its conduit function). Therefore, biodegradable micron-
eedles can provide an increased level of safety, as compared 
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to nonbiodegradable ones. The microneedles should be ster-
ilizable using standard methods. 
The microneedles can be formed of a porous solid, with or 
without a sealed coating or exterior portion, or hollow. As 
used herein, the term "porous" means having pores or voids 
throughout at least a portion of the microneedle structure, 
sufficiently large and sufficiently interconnected to permit 
passage of fluid and/or solid materials through the micron-
eedle. As used herein, the term "hollow" means having one or 
more substantially annular bores or channels through the 
interior of the microneedle structure, having a diameter suf-
ficiently large to permit passage of fluid and/or solid materials 
through the microneedle. The annular bores may extend 
throughout all or a portion of the needle in the direction of the 
tip to the base, extending parallel to the direction of the needle 
or branching or exiting at a side of the needle, as appropriate. 
A solid or porous microneedle can be hollow. One of skill in 
the art can select the appropriate porosity and/or bore features 
required for specific applications. For example, one can 
adjust the pore size or bore diameter to permit passage of the 
particular material to be transported through the microneedle 
device. 
The microneedles can have straight or tapered shafts. A 
hollow microneedle that has a substantially uniform diam-
eter, which needle does not taper to a point, is referred to 
herein as a "microtube." As used herein, the term "micron-
eedle" includes both microtubes and tapered needles unless 
otherwise indicated. In a preferred embodiment, the diameter 
of the microneedle is greatest at the base end of the micron-
eedle and tapers to a point at the end distal the base. The 
microneedle can also be fabricated to have a shaft that 
includes both a straight (untapered) portion and a tapered 
portion. 
The microneedles can be formed with shafts that have a 
circular cross-section in the perpendicular, or the cross-sec-
tion can be non-circular. For example, the cross-section of the 
microneedle can be polygonal (e.g. star-shaped, square, tri-
angular), oblong, or another shape. The shaft can have one or 
more bores. The cross-sectional dimensions typically are 
between about 10 nm and 1 mm, preferably between 1 micron 
and 200 microns, and more preferably between 10 and 100 
µm. The outer diameter is typically between about 10 µm and 
about 100 µm, and the inner diameter is typically between 
about 3 µm and about 80 µm. 
The length of the microneedles typically is between about 
1 µm and 1 mm, preferably between 10 microns and 500 
microns, and more preferably between 30 and 200 µm. The 
length is selected for the particular application, accounting 
for both an inserted and uninserted portion. An array of 
microneedles can include a mixture of microneedles having, 
for example, various lengths, outer diameters, inner diam-
eters, cross-sectional shapes, and spacings between the 
microneedles. 
The microneedles can be oriented perpendicular or at an 
angle to the substrate. Preferably, the microneedles are ori-
ented perpendicular to the substrate so that a larger density of 
microneedles per unit area of substrate can be provided. An 
array of microneedles can include a mixture of microneedle 
orientations, heights, or other parameters. 
In a preferred embodiment of the device, the substrate 
and/or microneedles, as well as other components, are formed 
from flexible materials to allow the device to fit the contours 
of the biological barrier, such as the skin, vessel walls, or the 
eye, to which the device is applied. A flexible device will 
facilitate more consistent penetration during use, since pen-
etration can be limited by deviations in the attachment sur-
6 
face. For example, the surface ofhuman skin is not flat due to 
dermatoglyphics (i.e. tiny wrinkles) and hair: 
c. Reservoir 
The microneedle device may include a reservoir in com-
munication with the microneedles. The reservoir can be 
attached to the substrate by any suitable means. In a preferred 
embodiment, the reservoir is attached to the back of the sub-
strate (opposite the microneedles) around the periphery, 
using an adhesive agent (e.g., glue). A gasket may also be 
10 used to facilitate formation of a fluid-tight seal. 
In a preferred embodiment, the reservoir contains drug, for 
delivery through the microneedles. The reservoir may be a 
hollow vessel, a porous matrix, or a solid form including drug 
which is transported therefrom. The reservoir can be formed 
15 from a variety of materials that are compatible with the drug 
or biological fluid contained therein. Preferred materials 
include natural and synthetic polymers, metals, ceramics, 
semiconductors, organics, and composites. 
The microneedle device can include one or a plurality of 
20 chambers for storing materials to be delivered. In the embodi-
ment having multiple chambers, each can be in fluid connec-
tion with all or a portion of the microneedles of the device 
array. In one embodiment, at least two chambers are used to 
separately contain drug (e.g., a lyophilized drug, such as a 
25 vaccine) and an administration vehicle (e.g., saline) in order 
to prevent or minimize degradation during storage. Immedi-
ately before use, the contents of the chambers are mixed. 
Mixing can be triggered by any means, including, for 
example, mechanical disruption (i.e. puncturing or breaking), 
30 changing the porosity, or electrochemical degradation of the 
walls or membranes separating the chambers. In another 
embodiment, a single device is used to deliver different drugs, 
which are stored separately in different chambers. In this 
embodiment, the rate of delivery of each drug can be inde-
35 pendently controlled. 
In a preferred embodiment, the reservoir should be in direct 
contact with the microneedles and have holes through which 
drug could exit the reservoir and flow into the interior of 
hollow or porous microneedles. In another preferred embodi-
40 ment, the reservoir has holes which permit the drug to trans-
port out of the reservoir and onto the skin surface. From there, 
drug is transported into the skin, either through hollow or 
porous microneedles, along the sides of solid microneedles, 
or through pathways created by microneedles in the skin. 
45 d. Transport Control Components 
The microneedle device also must be capable of transport-
ing material across the barrier at a useful rate. For example, 
the microneedle device must be capable of delivering drug 
across the skin at a rate sufficient to be therapeutically useful. 
50 The device may include a housing with microelectronics and 
other micromachined structures to control the rate of delivery 
either according to a preprogranimed schedule or through 
active interface with the patient, a healthcare professional, or 
a biosensor. The rate can be controlled by manipulating a 
55 variety of factors, including the characteristics of the drug 
formulation to be delivered (e.g., its viscosity, electric charge, 
and chemical composition); the dimensions of each micron-
eedle (e.g., its outer diameter and the area of porous or hollow 
openings); the number of microneedles in the device; the 
60 application of a driving force (e.g., a concentration gradient, 
a voltage gradient, a pressure gradient); and the use of a valve. 
The rate also can be controlled by interposing between the 
drug in the reservoir and the opening( s) at the base end of the 
microneedle polymeric or other materials selected for their 
65 diffusion characteristics. For example, the material composi-
tion and layer thickness can be manipulated using methods 
known in the art to vary the rate of diffusion of the drug of 
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interest through the material, thereby controlling the rate at 
which the drug flows from the reservoir through the micron-
eedle and into the tissue. 
Transportation of molecules through the microneedles can 
be controlled or monitored using, for example, various com-
binations of valves, pumps, sensors, actuators, and micropro-
cessors. These components can be produced using standard 
manufacturing or micro fabrication techniques. Actuators that 
may be useful with the microneedle devices disclosed herein 
include micropumps, microvalves, and positioners. In a pre- 10 
ferred embodiment, a microprocessor is programmed to con-
trol a pump or valve, thereby controlling the rate of delivery. 
Flow of molecules through the microneedles can occur 
based on diffusion, capillary action, or can be induced using 
conventional mechanical pumps or nonmechanical driving 15 
forces, such as electroosmosis or electrophoresis, or convec-
tion. For example, in electroosmosis, electrodes are posi-
tioned on the biological barrier surface, one or more micron-
eedles, and/or the substrate adjacent the needles, to create a 
convective flow which carries oppositely charged ionic spe- 20 
cies and/or neutral molecules toward or into the biological 
barrier. In a preferred embodiment, the microneedle device is 
used in combination with another mechanism that enhances 
the permeability of the biological barrier, for example by 
increasing cell uptake or membrane disruption, using electric 25 
fields, ultrasound, chemical enhancers, viruses, pH, heat and/ 
or light. 
8 
The microneedle may function as a conduit for fluids, 
solutes, electric charge, light, or other materials. In one 
embodiment, hollow microneedles can be filled with a sub-
stance, such as a gel, that has a sensing functionality associ-
ated with it. In an application for sensing based on binding to 
a substrate or reaction mediated by an enzyme, the substrate 
or enzyme can be immobilized in the needle interior, which 
would be especially useful in a porous needle to create an 
integral needle/sensor. 
Wave guides can be incorporated into the microneedle 
device to direct light to a specific location, or for dection, for 
example, using means such as a pH dye for color evaluation. 
Similarly, heat, electricity, light or other energy forms may be 
precisely transmitted to directly stimulate, damage, or heal a 
specific tissue or intermediary (e.g., tattoo remove for dark 
skinned persons), or diagnostic purposes, such as measure-
ment of blood glucose based on ER spectra or by chromato-
graphic means, measuring a color change in the presence of 
immobilized glucose oxidase in combination with an appro-
priate substrate. 
f. Attachment Features 
A collar or flange also can be provided with the device, for 
example, around the periphery of the substrate or the base. It 
preferably is attached to the device, but alternatively can be 
formed as integral part of the substrate, for example 
by'forming microneedles only near the center of an "over-
sized" substrate. The collar can also emanate from other parts 
of the device. The collar can provide an interface to attach the 
microneedle array to the rest of the device, and can facilitate 
handling of the smaller devices. 
In a preferred embodiment, the microneedle device 
includes an adhesive to temporarily secure the device to the 
surface of the biological barrier. The adhesive can be essen-
Passage of the microneedles, or drug to be transported via 
the microneedles, can be manipulated by shaping the micron-
eedle surface, or by selection of the material forming the 30 
microneedle surface (which could be a coating rather than the 
microneedle per se ). For example, one or more grooves on the 
outside surface of the microneedles can be used to direct the 
passage of drug, particularly in a liquid state. Alternatively, 
the physical surface properties of the microneedle could be 
manipulated to either promote or inhibit transport of material 
along the microneedle surface, such as by controlling hydro-
philicity or hydrophobicity. 
35 tially anywhere on the device to facilitate contact with the 
biological barrier. For example, the adhesive can be on the 
surface of the collar (same side as microneedles), on the 
surface of the substrate between the microneedles (near the 
The flow of molecules can be regulated using a wide range 
of valves or gates. These valves can be the type that are 40 
selectively and repeatedly opened and closed, or they can be 
single-use types. For example, in a disposable, single-use 
drug delivery device, a fracturable barrier or one-way gate 
may be installed in the device between the reservoir and the 
opening of the microneedles. When ready to use, the barrier 45 
can be broken or gate opened to permit flow through the 
microneedles. Other valves or gates used in the microneedle 
devices can be activated thermally, electrochemically, 
mechanically, or magnetically to selectively initiate, modu-
late, or stop the flow of molecules through the needles. In a 50 
preferred embodiment, flow is controlled by using a rate-
limiting membrane as a "valve." 
The microneedle devices can further include a flowmeter 
base of the microneedles), or a combination thereof. 
g. Transdermal Microneedle Device 
FIG. la is a side elevational view of a schematic of a 
preferred embodiment of the microneedle device inserted 
into skin. The device 10 includes an upper portion or substrate 
11 from which a plurality of microneedles 12 protrude. The 
height of the upper portion 11 is between about 1 µm and 1 
cm, and thewidthoftheupperportionis between about 1 mm 
and 10 cm. The upper portion 11 of the device can be solid or 
hollow, and may include multiple compartments. In a pre-
ferred embodiment for drug delivery, the upper portion 11 
contains one or more drugs to be delivered. It is also preferred 
that the upper portion include one or more sensors 12 and/or 
an apparatus (e.g., pump or electrode) to drive (provide/direct 
the force) transport of the drug or other molecules. 
The height (or length) of the microneedles 12 generally is or other means to monitor flow through the microneedles and 
to coordinate use of the pumps and valves. 
e. Sensors 
Useful sensors may include sensors of pressure, tempera-
ture, chemicals, and/or electro-magnetic fields. Biosensors 
can be located on the microneedle surface, inside a hollow or 
porous microneedle, or inside a device in communication 
with the body tissue via the microneedle (solid, hollow, or 
porous). These microneedle biosensors can include four 
classes of principal transducers: potentiometric, amperomet-
ric, optical, and physiochemical. An amperometric sensor 
monitors currents generated when electrons are exchanged 
between a biological system and an electrode. Blood glucose 
sensors frequently are of this type. 
55 between about 1 µm and 1 mm. The diameter and length both 
affect pain as well as functional properties of the needles. In 
transdermal: applications, the "insertion depth" of the 
microneedles 12 is preferably less than about 100 µm, more 
preferably about 30 µm, so that insertion of the microneedles 
60 12 into the skin through the stratum corneum 14 does not 
penetrate past the epidermis 16 into the dermis 18 (as 
described below), thereby avoiding contacting nerves and 
reducing the potential for causing pain. In such applications, 
the actual length of the microneedles may be longer, since the 
65 portion of the microneedles distal the tip may not be inserted 
into the skin; the uninserted length depends on the particular 
device design and configuration. The actual (overall) height 
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or length of microneedles 12 should be equal to the insertion ii. Plasma Etching 
depth plus the uninserted length. This process uses deep plasma etching of silicon to create 
The diameter of each microneedle 12 generally is between microneedles with diameters on the order of0.1 µm or larger. 
about 10 nm and 1 mm, and preferably leaves a residual hole Needles are patterned directly using photo lithography, rather 
(following microneedle insertion and withdrawal) ofless than than indirectly by controlling the voltage (as in electrochemi-
about 1 µm, to avoid making a hole which would allow cal etching), thus providing greater control over the final 
bacteria to enter the penetration wound. The actual micron- microneedle geometry. 
eedle diameter should be larger than 1 µm, since the hole In this process, an appropriate masking material (e.g., 
likely will contract following withdrawal of the microneedle. metal) is deposited onto a silicon wafer substrate and pat-
10 terned into dots having the diameter of the desired micron-The diameter of microneedle 12 more preferably is between 
b t 1 d loo L d. t d 1 . eedles. The wafer is then subjected to a carefully controlled a ou µman µm. arger rnme er an anger m1cron- plasma based on fluorine/oxygen chemistries to etch very 
eedles are acceptable, so long as the microneedle can pen- deep, high aspect ratio trenches into the silicon. See, e.g., 
etrate the biological barrier to the desired depth and the hole Jansen, et al., "The Black Silicon Method IV: The Fabrication 
remaining in the skin or other tissue following withdrawal of 15 ofThree-Dimensional Structures in Silicon with HighAspect 
the microneedle is sufficiently small, preferably small enough Ratios for Scanning Probe Microscopy and Other Applica-
to exclude bacterial entry. The microneedles 12 can be solid tions," IEEE Proceedings of Micro Electro Mechanical Sys-
or porous, and can include one or more bores connected to terns Conference, pp. 88-93 (1995). Those regions protected 
upper portion 11. by the metal mask remain and form the needles. This method 
3. Methods of Making Microneedle Devices 20 is further described in Example 1 below. FIG. lb provides a 
The microneedle devices are made by micro fabrication diagram of microneedles fabricated by this method. 
processes, by creating small mechanical structures in silicon, iii. Electroplating 
metal, polymer, and other materials. These microfabrication In this process, a metal layer is first evaporated onto a 
processes are based on well-established methods used to planar substrate. A layer of photoresist is then deposited onto 
make integrated circuits, electronic packages and other 25 the metal to form a patterned mold which leaves an exposed-
microelectronic devices, augmented by additional methods metal region in the shape of needles. By electroplating onto 
used in the field of micromachining. The microneedle devices the exposed regions of the metal seed layer, the mold bounded 
can have dimensions as small as a few nanometers and can be by photoresist can be filled with electroplated material. 
mass-produced at low per-unit costs. Finally, the substrate and photoresist mold are removed, leav-
a. Microfabrication Processes 30 ing the finished microneedle array. The microneedles pro-
duced by this process generally have diameters on the order of Micro fabrication processes that may be used in making the 1 µm or larger. See, e.g., Frazier, et al., "Two dimensional 
microneedles disclosed herein include lithography; etching 
metallic microelectrode arrays for extracellular stimulation 
techniques, such as wet chemical, dry, and photoresist 
and recording of neurons", IEEE Proceedings of the Micro 
removal; thermal oxidation of silicon; electroplating and 35 ElectroMechanicalSystemsConference,pp.195-200(1993). 
electro less plating; diffusion processes, such as boron, phos- iv. Other Processes 
phorus, arsenic, and antimony diffusion; ion implantation; Another method for forming microneedles made of silicon 
film deposition, such as evaporation (filament, electron beam, or other materials is to use micro fabrication techniques such 
flash, and shadowing and step coverage), sputtering, chemi- as photo lithography, plasma etching, or laser ablation to make 
cal vapor deposition (CVD), epitaxy (vapor phase, liquid 40 a mold form (A), transferring that mold form to other mate-
phase, and molecular beam), electroplating, screen printing, rials using standard mold transfer techniques, such as 
lamination, stereolithography, laser machining, and laser embossing or injection molding (B), and reproducing the 
ablation (including projection ablation). See generally Jaeger, shape of the original mold form (A) using the newly-created 
Introduction to Microelectronic Fabrication (Addison-Wes- mold (B) to yield the final microneedles (C). Alternatively, 
ley Publishing Co., Reading Mass. 1988); Runyan, et al., 45 the creation of the mold form (A) could be skipped and the 
Semiconductor Integrated Circuit Processing Technology mold (B) could be micro fabricated directly, which could then 
(Addison-Wesley Publishing Co., Reading Mass. 1990); Pro- be used to create the final microneedles (C). 
ceedings of the IEEE Micro Electro Mechanical Systems Another method of forming solid silicon microneedles is 
Conference 1987-1998; Rai-Choudhury, ed., Handbook of by using epitaxial growth on silicon substrates, as is utilized 
Microlithography, Micromachining & Microfabrication 50 by Containerless Research, Inc. (Evanston, Ill., USA) for its 
(SPIE Optical Engineering Press, Bellingham, Wash. 1997). products. 
The following methods are preferred for making micron- b. Hollow or Porous Microneedles 
eedles. 
i. Electrochemical Etching of Silicon 
In a preferred embodiment, microneedles are made with 
pores or other pathways through which material may be trans-
55 ported. The following descriptions outline representative 
methods for fabricating either porous or hollow micron-
eedles. 
In this method, electrochemical etching of solid silicon to 
porous silicon is used to create extremely fine (on the order of 
0.01 µm) silicon networks which can be used as piercing 
structures. This method uses electrolytic anodization of sili-
con in aqueous hydrofluoric acid, potentially in combination 
with light, to etch channels into the silicon. By varying the 60 
doping concentration of the silicon wafer to be etched, the 
electrolytic potential during etching, the incident light inten-
sity, and the electrolyte concentration, control over the ulti-
mate pore structure can be achieved. The material not etched 
(i.e. the silicon remaining) forms the microneedles. This 65 
method has been used to produce irregular needle-type struc-
tures measuring tens of nanometers in width. 
i. Porous Microneedles 
Rather than having' a single, well-defined hole down the 
length of the needle, porous needles are filled with a network 
of channels or pores which allow conduction of fluid or 
energy through the needle shaft. It has been shown that by 
appropriate electrochemical oxidation of silicon, pore arrays 
with high aspect ratios and a range of different pore size 
regimes can be formed; these pore regimes are defined as (1) 
microporous regime with average pore dimensions less than 2 
nm, (2) mesoporous regime with average pore sizes of 
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between 2 run and 50 run, and (3) macroporous regime with 
pores greater than 50 run. The mesoporous and macroporous 
regimes are expected to be most useful for drug delivery. Two 
approaches to porous needles are generally available, either 
12 
layer 84 on top of the wafer 82. The wafer 82 is anisotrophi-
cally etched (FIG. 2b) to form a cavity 86 through its entire 
thickness (FIG. 2c). The wafer 82 is then coated with a chro-
mium layer 88 followed by a second photoresist layer 90 
patterned so as to cover the cavity 86 andforma circular mask 
for subsequent etching (FIG. 2d). The wafer 32 is then etched 
by a standard etch to form the outer tapered walls 92 of the 
microneedle (FIG. 2e). 
Alternatively, this structure can be achieved by substituting 
1 o the chromium mask used for the solid microneedles described 
(a) the silicon wafer is first made porous and then etched as 
described above to form needles or (b) solid microneedles are 
etched and then rendered porous, for example, by means of 
electrochemical oxidation, such as by anodization of a silicon 
substrate in a hydrofluoric acid electrolyte. The size distribu-
tion of the etched porous structure is highly dependent on 
several variables, including doping kind and illumination 
conditions, as detailed in Lehmann, "Porous Silicon-A New 
Material for MEMS", IEEE Proceedings of the Micro Electro 
Mechanical Systems Conference, pp. 1-6 (1996). Porous 
polymer or metallic microneedles can be formed, for 15 
example, by micromolding a polymer containing a volatiliz-
able or leachable material, such as a volatile salt, dispersed in 
the polymer or metal, and then volatilizing or leaching the 
dispersed material, leaving a porous polymer matrix in the 
shape of the microneedle. 
in Example 1 by a silicon nitride layer 94 on the silicon 
substrate 95 covered with chromium 96, deposited as shown 
in FIG. 3a and patterned as shown in FIG. 3b. Solid micron-
eedles are then etched as described in Example 1 as shown 
FIG. 3c, the chromium 96 is stripped (FIG. 3d), and the 
silicon 95 is oxidized to form a thin layer of silicon dioxide 97 
on all exposed silicon surfaces (FIG. 3e). The silicon nitride 
layer 94 prevents oxidation at the needle tip. The silicon 
nitride 94 is then stripped (FIG. 30, leaving exposed silicon at 
ii. Hollow Needles 
Three-dimensional arrays of hollow microneedles can be 
fabricated, for example, using combinations of dry etching 
processes (Laermer, et al., "Bosch Deep Silicon Etching: 
20 the tip of the needle and oxide-covered silicon 97 everywhere 
else. The needle is then exposed to an ICP plasma which 
selectively etches the inner sidewalls of the silicon 95 in a 
highly anisotropic manner to form the interior hole of the 
Improving Uniformity and Etch Rate for Advanced MEMS 25 
Applications," Micro Electro Mechanical Systems, Orlando, 
Fl., USA, (Jan. 17-21, 1999); Despont et al., "High-Aspect-
Ratio, Ultrathick, Negative-Tone Near-UV Photoresist for 
MEMS", Proc. of IEEE lO'h Annual International Workshop 
on MEMS, Nagoya, Japan, pp. 518-522 (Jan. 26-30, 1997)); 30 
micromold creation in lithographically-defined and/or laser 
ablated polymers and selective sidewall electroplating; or 
direct micromolding techniques using epoxy mold transfers. 
One or more distinct and continuous pathways are created 
through the interior ofmicroneedles. In a preferred embodi- 35 
ment, the microneedle has a single annular pathway along the 
center axis of the microneedle. This pathway can be achieved 
by initially chemically or physically etching the holes in the 
material and then etching away microneedles around the hole. 
Alternatively, the microneedles and their holes can be made 40 
simultaneously or holes can be etched into existing micron-
eedles. As another option, a microneedle form or mold can be 
made, then coated, and then etched away, leaving only the 
outer coating to form a hollow microneedle. Coatings can be 
formed either by deposition of a film or by oxidation of the 45 
silicon microneedles to a specific thickness, followed by 
removal of the interior silicon. Also, holes from the backside 
needle (FIG. 3g). 
Another method uses the solid silicon needles described 
previously as 'forms' around which the actual needle struc-
tures are deposited. After deposition, the forms are etched 
away, yielding the hollow structures. Silica needles or metal 
needles can be formed using different methods. Silica needles 
can be formed by creating needle structures similar to the ICP 
needles described above prior to the oxidation described 
above. The wafers are then oxidized to a controlled thickness, 
forming a layer on the shaft of the needle form which will 
eventually become the hollow microneedle. The silicon 
nitride is then stripped and the silicon core selectively etched 
away (e.g., in a wet alkaline solution) to form a hollow silica 
microneedle. 
In a preferred embodiment, an array of hollow silicon 
microtubes is made using deep reactive ion etching combined 
with a modified black silicon process in a conventional reac-
tive ion etcher, as described in Example 3 below. First, arrays 
of circular holes are patterned through photoresist into Si02 , 
such as on a silicon wafer. Then the silicon can be etched 
using deep reactive ion etching (DRIE) in an inductively 
coupled plasma (ICP) reactor to etch deep vertical holes. The 
photoresist was then removed. Next, a second photolithogra-
phy step patterns the remaining Si02 layer into circles con-
centric to the holes, leaving ring shaped oxide masks sur-
rounding the holes. The photoresist is then removed and the 
of the wafer to the underside of the hollow needles can be 
created using a front-to-backside infrared aligrunent followed 
by etching from the backside of the wafer. 
a. Silicon Microneedles 
One method for hollow needle fabrication is to replace the 
solid mask used in the formation of solid needles by a mask 
that includes a solid shape with one or more interior regions of 
the solid shape removed. One example is a "donut-shaped" 
mask. Using this type of mask, interior regions of the needle 
are etched simultaneously with their side walls. Due to lateral 
etching of the inner side walls of the needle, this may not 
produce sufficiently sharp walls. In that case, two plasma 
etches may be used, one to form the outer walls of the micron-
eedle (i.e., the 'standard' etch), and one to form the inner 
hollow core (which is an extremely anisotropic etch, such as 
50 silicon wafer again deep silicon etched, such that the holes are 
etched completely through the wafer (inside the Si02 ring) 
and simultaneously the silicon is etched around the Si02 ring 
leaving a cylinder. 
This tatter process can be varied to produce hollow, tapered 
55 microneedles. After an array of holes is fabricated as 
described above, the photoresist and Si02 layers are replaced 
with conformal DC sputtered chromium rings. The second 
ICP etch is replaced with a SF 6/02 plasma etch in a reactive 
ion etcher (RIE), which results in positively sloping outer 
60 sidewalls. Henry, et al., "Micromachined Needles for the 
Transdermal Delivery of Drugs," Micro Electro Mechanical 
Systems, Heidelberg, Germany, pp. 494-498 (Jan. 26-29, 
1998). in inductively-coupled-plasma "ICP" etch). For example, the 
ICP etch can be used to form the interior region of the needle 
followed by a second photolithography step and a standard 65 
etch to form the outer walls of the microneedle. FIG. 2a 
represents a silicon wafer 82 with a patterned photoresist 
b. Metal Microneedles 
Metal needles can be formed by physical vapor deposition 
of appropriate metal layers on solid needle forms, which can 
be made of silicon using the techniques described above, or 
US 8, 708,966 B2 
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which can be formed using other standard mold techniques 
such as embossing or injection molding. The metals are selec-
tively removed from the tips of the needles using electropol-
ishing techniques, in which an applied anodic potential in an 
electrolytic solution will cause dissolution of metals more 
rapidly at sharp points, due to concentration of electric field 
lines at the sharp points. Once the underlying silicon needle 
forms have been exposed at the tips, the silicon is selectively 
etched away to form hollow metallic needle structures. This 
process could also be used to make hollow needles made from 
other materials by depositing a material other than metal on 
the needle forms and following the procedure described 
above. 
14 
the art can be exposed and developed in such as way as to have 
the surface immediately adjacent to the mask be wider than 
the other surface. Specialized greyscale photoresists in com-
bination with greyscale masks can accomplish the same 
effect. Laser-ablated molds can also be made with tapered 
sidewalls, e.g., by optical adjustment of the beam (in the case 
of serial hole fabrication) or of the reticle or mold during 
ablation (in the case of projection ablation). Alternatively, 
non-vertical sidewalls can be produced directly in the poly-
10 meric mold into which electroplating will take place. For 
example, conventional photoresists know in the art can be 
exposed and developed in such a way as to have surface 
immediately adjacent to the mask be wider than the other 
surface. Specialized greyscale photoresists in combination A preferred method of fabricating hollow metal micron-
eedles utilizes micromold plating techniques, for example 
which are described as follows and in Examples 4 and 5. In a 
method for making metal microtubes, which does not require 
dry silicon etching, a photo-defined mold first is first pro-
duced, for example, by spin casting a thick layer, typically 
150 µm, of an epoxy (e.g., SU-8) onto a substrate that has 20 
been coated with a thin sacrificial layer, typically about 10 to 
15 with greyscale masks can accomplish the same effect. Laser-
ablated molds can also be made with tapered sidewalls, e.g., 
by optical adjustment of the beam (in the case of serial hole 
fabrication) or of the reticle or mold during ablation (in the 
case of projection ablation). 
To form hollow tapered microneedles, the mold-insert is an 
array of solid silicon microneedles, formed as described in 
Henry, et al., "Micromachined Needles for the Transdermal 
Delivery of Drugs," Micro Electro Mechanical Systems, 
Heidelberg, Germany, Jan. 26-29, pp. 494-498 (1998). First, 
50 nm. Arrays of cylindrical holes are then photo lithographi-
cally defined through the epoxy layer, which typically is 
about 150 µm thick. (Despont, et al., "High-Aspect-Ratio, 
Ultrathick, Negative-Tone Near-UV Photoresist for MEMS," 
Proc. of IEEE 1 O'h Annual International Workshop on MEMS, 
Nagoya, Japan, pp. 518-522 (Jan. 26-30, 1997)). The diam-
eterofthese cylindrical holes defines the outer diameter of the 
tubes. The upper surface of the substrate, the sacrificial layer, 
is then partially removed atthe bottom of the cylindrical holes 
in the photoresist. The exact method chosen depends on the 
choice of substrate. For example, the process has been suc-
cessfully performed on silicon and glass substrates (in which 
the upper surface is etched using isotropic wet or dry etching 
techniques) and copper-clad printed wiring board substrates. 
In the latter case, the copper laminate is selectively removed 
using wet etching. Then a seed layer, such as Ti/Cu/Ti (e.g., 
30 nm/200 mu/30 nm), is conformally DC sputter-deposited 
onto the upper surface of the epoxy mold and onto the side-
walls of the cylindrical holes. The seed layer should be elec-
trically isolated from the substrate. Subsequently, one or 
more electroplatable metals or alloys, such as Ni, NiFe, Au, 
Cu, or Ti are electroplated onto the seed layer. The surround-
ing epoxy is then removed, leaving microtubes which each 
have an interior annular hole that extends through the base 
metal supporting the tubes. The rate and duration of electro-
plating is controlled in order to define the wall thickness and 
inner diameter of the microtubes. In one embodiment, this 
method was used to produce microtubes having a height of 
between about 150 and 250 µm, an outer diameter of between 
about 40 and 120 µm, and an inner diameter of between about 
30 and 110 µm (i.e., having thickness of 10 µm). In a typical 
array, the microtubes have a tube center-to-center spacing of 
about 150 µm, but can vary depending on the desired needle 
density. 
25 a layer of a material, such as an epoxy (e.g., SU-8), is spin cast 
onto the array of silicon microneedles to completely blanket 
the entire array. The epoxy settles during pre-bake to create a 
planar surface above the silicon needle tips; the material is 
then fully pre-baked, photolithographically cross-linked, and 
30 post-baked. 
The upper surface of the epoxy is then etched away, for 
example with an 0iCHF3 plasma, until the needle tips are 
exposed, preferably leaving between about 1 and 5 µm of tip 
protruding from the epoxy. The silicon is then selectively 
35 removed, for example by using a SF 6 plasma or a HN03 /HE 
solution. The remaining epoxy micromold is the negative of 
the microneedles and has a small diameter hole where the tip 
of the microneedle formerly protruded. 
After the removal of the silicon, a seed layer, such as 
40 Ti-Cu-Ti is conformally sputter-deposited onto the epoxy 
micromold. Following the same process sequence described 
for hollow metal microtubes, one or more electroplatable 
metals or alloys, such as Ni, NiFe, Au, or Cu, are electroplated 
onto the seed layer. Finally, the epoxy is removed, for 
45 example by using an 0 2 /CHF 3 plasma, leaving an array of 
hollow metal microneedles. In a preferred embodiment, this 
method is used to produce microneedles having a height of 
between about 150 and 250 µm, an outer diameter of between 
about 40 and 120 µm, and an inner diameter of between about 
50 50 and 100 µm. In a typical array, the microtubes have a tube 
center-to-center spacing of about 150 µm, but can vary 
depending on the desired needle density. The microneedles 
are 150 µm in height with a base diameter of 80 µm, a tip 
55 
diameter of 10 µm, and a needle to needle spacing of 150 µm. 
c. Silicon Dioxide Microneedles 
A variation of this method is preferred for forming tapered 
microneedles. As described above, photolithography yields 
holes in the epoxy which have vertical sidewalls, such that the 
resulting shafts of the microneedles are straight, not tapered. 
This vertical sidewall limitation can be overcome by molding 60 
a preexisting 3D structure, i.e., a mold-insert. The subsequent 
removal of the mold-insert leaves a mold which can be sur-
face plated similarly to the holes produced by photolithogra-
phy described above. 
Hollow microneedles formed of silicon dioxide can be 
made by oxidizing the surface of the silicon microneedle 
forms (as described above), rather than depositing a metal and 
then etching away the solid needle forms to leave the hollow 
silicon dioxide structures. This method is illustrated in FIGS. 
4a-4d. FIG. 4a shows an array 24 of needle forms 26 with 
masks 28 on their tips. In FIG. 4b, the needle forms 26 have 
been coated with a layer 30 of metal, silicon dioxide or other 
material. FIG. 4c shows the coated needle forms 26 with the 
Alternatively, non-vertical sidewalls can be produced 65 
directly in the polymeric mold into which electroplating will 
take place. For example, conventional photoresists known in 
masks 28 removed. Finally, in FIG. 4d, the needle forms 26 
have been etched away, leaving hollow needles 30 made of 
metal, silicon dioxide, or other materials. 
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In one embodiment, hollow, porous, or solid microneedles 
are provided with longitudinal grooves or other modifications 
to the exterior surface of the microneedles. Grooves, for 
example, should be useful in directing the flow of molecules 
along the outside of microneedles. 
d. Polymer Microneedles 
In a preferred method, polymeric microneedles are made 
using microfabricated molds. For example, the epoxy molds 
can be made as described above and injection molding tech-
niques can be applied to form the microneedles in the molds 10 
(Weber, et al., "Micromolding-a powerful tool for the large 
scale production of precise microstructures", Proc. SPIE-
International Soc. Optical Engineer. 2879, 156-167 (1996); 
Schift, et al., "Fabrication of replicated high precision insert 
elements for micro-optical bench arrangements" Proc. 15 
SPIE-International Soc. Optical Engineer. 3513, 122-134 
(1998). These micromolding techniques are preferred over 
other techniques described herein, since they can provide 
relatively less expensive replication, i.e. lower cost of mass 
production. In a preferred embodiment, the polymer is bio- 20 
degradable. 
4. Microneedle Device Applications 
The device may be used for single or multiple uses for rapid 
transport across a biological barrier or may be left in place for 
longer times (e.g., hours or days) for long-term transport of 25 
molecules. Depending on the dimensions of the device, the 
application site, and the route in which the device is intro-
duced into (or onto) the biological barrier, the device may be 
used to introduce or remove molecules at specific locations. 
As discussed above, FIG. 1 shows a side elevational view 30 
of a schematic of a preferred embodiment of the microneedle 
device 10 in a transdermal application. The device 10 is 
applied to the skin such that the microneedles 12 penetrate 
through the stratum corneum and enter the viable epidermis 
so that the tip of the microneedle at least penetrates into the 35 
viable epidermis. In a preferred embodiment, drug molecules 
16 
treatment or for regional or systemic therapy. The following 
are representative examples, and disorders they are used to 
treat: 
Calcitonin, osteoporosis 
Enoxaprin, anticoagulant 
Etanercept, rheumatoid arthritis 
Erythropoietin, anemia 
Fentanyl, postoperative and chronic pain 
Filgrastin, low white blood cells from chemotherapy 
Heparin, anticoagulant 
Insulin, human, diabetes 
Interferon Beta la, multiple sclerosis 
Lidocaine, local anesthesia 
Somatropin, growth hormone 
Sumatriptan, migraine headaches 
In this way, many drugs can be delivered at a variety of 
therapeutic rates. The rate can be controlled by varying a 
number of design factors, including the outer diameter of the 
microneedle, the number and size of pores or channels in each 
microneedle, the number of microneedles in an array, the 
magnitude and frequency of application of the force driving 
the drug through the microneedle and/or the holes created by 
the microneedles. For example, devices designed to deliver 
drug at different rates might have more microneedles for 
more rapid delivery and fewer microneedles for less rapid 
delivery. As another example, a device designed to deliver 
drug at a variable rate could vary the driving force (e.g., 
pressure gradient controlled by a pump) for transport accord-
ing to a schedule which was pre-progranmied or controlled 
by, for example, the user or his doctor. The devices can be 
affixed to the skin orothertissue to deliver drugs continuously 
or intermittently, for durations ranging from a few seconds to 
several hours or days. 
One of skill in the art can measure the rate of drug delivery 
for particular microneedle devices using in vitro and in vivo 
methods known in the art. For example, to measure the rate of 
transdermal drug delivery, human cadaver skin mounted on 
standard diffusion chambers can be used to predict actual 
rates. See Hadgraft & Guy, eds., Transdermal Drug Delivery: 
in a reservoir within the upper portion 11 flow through or 
around the microneedles and into the viable epidermis, where 
the drug molecules then diffuse into the dermis for local 
treatment or for transport through the body. 40 Developmental Issues and Research Initiatives (Marcel Dek-
ker, New York 1989); Bronaugh & Maibach, Percutaneous 
Absorption, Mechanisms-Methodology-Drug Delivery 
(Marcel Dekker, New York 1989). After filling the compart-
To control the transport of material out of or into the device 
through the microneedles, a variety of forces or mechanisms 
can be employed. These include pressure gradients, concen-
tration gradients, electricity, ultrasound, receptor binding, 
heat, chemicals, and chemical reactions. Mechanical or other 45 
gates in conjunction with the forces and mechanisms 
described above can be used to selectively control transport of 
the material. 
In particular embodiments, the device should be "user-
friendly." For example, in some transdermal applications, 
affixing the device to the skin should be relatively simple, and 
not require special skills. This embodiment of a microneedle 
may include an array of microneedles attached to a housing 
containing drug in an internal reservoir, wherein the housing 
has a bioadhesive coating around the microneedles. The 
patient can remove a peel-away backing to expose an adhe-
sive coating, and then press the device onto a clean part of the 
skin, leaving it to administer drug over the course of, for 
example, several days. 
a. Drug Delivery 
ment on the dermis side of the diffusion chamber with saline, 
a microneedle array is inserted into the stratum corneum; a 
drug solution is placed in the reservoir of the microneedle 
device; and samples of the saline solution are taken over time 
and assayed to determine the rates of drug transport. 
In an alternate embodiment, biodegradable or non-biode-
50 gradable microneedles can be used as the entire drug delivery 
device, where biodegradable microneedles are a preferred 
embodiment. For example, the microneedles may be formed 
of a biodegradable polymer containing a dispersion of an 
active agent for local or systemic delivery. The agent could be 
55 released over time, according to a profile determined by the 
composition and geometry of the microneedles, the concen-
tration of the drug and other factors. In this way, the drug 
reservoir is within the matrix of one or more of the micron-
eedles. 
60 
Essentially any drug or other bioactive agents can be deliv-
ered using these devices. Drugs can be proteins, enzymes, 
polysaccharides, polynucleotide molecules, and synthetic 
organic and inorganic compounds. A preferred drug is insu-
lin. Representative agents include anti-infectives, hormones, 65 
growth regulators, drugs regulating cardiac action or blood 
flow, and drugs for pain control. The drug can be for local 
In another alternate embodiment, these microneedles may 
be purposefully sheared off from the substrate after penetrat-
ing the biological barrier. In this way, a portion of the micron-
eedles would remain within or on the other side of the bio-
logical barrier and a portion of the microneedles and their 
substrate would be removed from the biological barrier. In the 
case of skin, this could involve inserting an array into the skin, 
manually or otherwise breaking off the microneedles tips and 
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then remove the base of the microneedles. The portion of the 
microneedles which remains in the skin or in or across 
another biological barrier could then release drug over time 
according to a profile determined by the composition and 
geometry of the microneedles, the concentration of the drug 
and other factors. In a preferred embodiment, the micron-
eedles are'made of a biodegradable polymer. The release of 
drug from the biodegradable microneedle tips could be con-
trolled by the rate of polymer degradation. Microneedle tips 
could release drugs for local or systemic effect, but could also 10 
release other agents, such as perfume, insect repellent and sun 
block. 
Microneedle shape and content could be designed to Con-
trol the breakage of microneedles. For example, a notch could 
18 
In an alternate embodiment, microneedles may be pur-
posefully sheared off from the substrate after penetrating the 
biological barrier, as described above. The portion of the 
microneedles which remain within or on the other side of the 
biological barrier could contain one or more biosensors. For 
example, the sensor could change color as its output. For 
microneedles sheared off in the skin, this color change could 
be observed through the skin by visual inspection or with the 
aid of an optical apparatus. 
Other than transport of drugs and biological molecules, the 
microneedles may be used to transmit or transfer other mate-
rials and energy forms, such as light, electricity, heat, or 
pressure. The microneedles, for example, could be used to 
direct light to specific locations within the body, in order that 
15 the light can directly act on a tissue or on an intermediary, 
such as light-sensitive molecules in photodynamic therapy. 
The microneedles can also be used for aerosolization or deliv-
ery for example directly to a mucosa! surface in the nasal or 
be introduced into microneedles either at the time of fabrica-
tion or as a subsequent step. In this way, microneedles would 
preferentially break at the site of the notch. Moreover, the size 
and shape of the portion of microneedles which break off 
could be controlled not only for specific drug release patterns, 
but also for specific interactions with cells in the body. For 20 
example, objects of a few microns in size are known to be 
taken up by macrophages. The portions of microneedles that 
break off could be controlled to be bigger or smaller than that 
buccal regions or to the pulmonary system. 
The microneedle devices disclosed herein also should be 
useful for controlling transport across tissues other than skin. 
For example, microneedles could be inserted into the eye 
across, for example, conjunctiva, sclera, and/or cornea, to 
facilitate delivery of drugs into the eye. Similarly, micron-to prevent uptake by macrophages or could be that size to 
promote uptake by macrophages, which could be desirable 
for delivery of vaccines. 
b. Diagnostic Sensing of Body Fluids (Biosensors) 
One embodiment of the devices described herein may be 
used to remove material from the body across a biological 
barrier, i.e. for minimally invasive diagnostic sensing. For 
example, fluids can be transported from interstitial fluid in a 
tissue into a reservoir in the upper portion of the device. The 
fluid can then be assayed while in the reservoir or the fluid can 
25 eedles inserted into the eye could facilitate transport of fluid 
out of the eye, which may be of benefit for treatment of 
glaucoma. Microneedles may also be inserted into the buccal 
(oral), nasal, vaginal, or other accessible mucosa to facilitate 
transport into, out of, or across those tissues. For example, a 
be removed from the reservoir to be assayed, for diagnostic or 
other purposes. For example, interstitial fluids can be 
removed from the epidermis across the stratum corneum to 
assay for glucose concentration, which should be useful in 
aiding diabetics in determining their required insulin dose. 
Other substances or properties that would be desirable to 
detect include lactate (important for athletes), oxygen, pH, 
alcohol, tobacco metabolites, and illegal drugs (important for 
both medical diagnosis and law enforcement). 
30 drug may be delivered across the buccal mucosa for local 
treatment in the mouth or for systemic uptake and delivery. As 
another example, microneedle devices may be used internally 
within the body on, for example, the lining of the gastrointes-
tinal tract to facilitate uptake of orally-ingested drugs or the 
35 lining of blood vessels to facilitate penetration of drugs into 
the vessel wall. For example, cardiovascular applications 
include using microneedle devices to facilitate vessel disten-
sion or immobilization, similarly to a stent, wherein the 
microneedles/substrate can function as a "staple-like" device 
40 to penetrate into different tissue segments and hold their 
relative positions for a period of time to permit tissue regen-
eration. This application would be particularly useful with 
biodegradable devices. These uses may involve invasive pro-
cedures to introduce the microneedle devices into the body or 
The sensing device can be in or attached to one or more 
microneedles, or in a housing adapted to the substrate. Sens-
ing information or signals can be transferred optically (e.g., 
refractive index) or electrically (e.g., measuring changes in 
electrical impedance, resistance, current, voltage, or combi-
nation thereof). For example, it may be useful to measure a 
change as a function of change in resistance of tissue to an 
electrical current or voltage, or a change in response to chan- 50 
nel binding or other criteria (such as an optical change) 
wherein different resistances are calibrated to signal that 
more or less flow of drug is needed, or that delivery has been 
completed. 
45 could involve swallowing, inhaling, injecting or otherwise 
introducing the devices in a non-invasive or minimally-inva-
In one embodiment, one or more microneedle devices can 55 
be used for (1) withdrawal of interstitial fluid, (2) assay of the 
fluid, and/or (3) delivery of the appropriate amount ofa thera-
peutic agent based on the results of the assay, either automati-
cally or with human intervention. For example, a sensor deliv-
ery system may be combined to form, for example, a system 60 
which withdraws bodily fluid, measures its glucose content, 
and delivers an appropriate amount of insulin. The sensing or 
delivery step also can be performed using conventional tech-
niques, which would be integrated into use of the microneedle 
device. For example, the microneedle device could be used to 65 
withdraw and assay glucose, and a conventional syringe and 
needle used to administer the insulin, or vice versa. 
s1ve manner. 
The present invention will be further understood with ref-
erence to the following non-limiting examples. 
EXAMPLE 1 
Fabrication of Solid Silicon Microneedles 
A chromium masking material was deposited onto silicon 
wafers and patterned into dots having a diameter approxi-
mately equal to the base of the desired microneedles. The 
wafers were then loaded into a reactive ion etcher and sub-
jected to a carefully controlled plasma based on fluorine/ 
oxygen chemistries to etch very deep, high aspect ratio val-
leys into the silicon. Those regions protected by the metal 
mask remain and form the microneedles. 
<100>-oriented, prime grade, 450-550 µm thick, 10-15 
Q-cm silicon wafers (Nova Electronic Materials Inc., Rich-
ardson, Tex.) were used as the starting material. The wafers 
were cleaned in a solution of 5 parts by volume deionized 
water, 1 part 30% hydrogen peroxide, and 1 part 30% ammo-
US 8, 708,966 B2 
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nium hydroxide (J. T. Baker, Phillipsburg, N.J.) at approxi-
mately 80° C. for 15 minutes, and then dried in an oven (Blue 
M Electric, Watertown, Wis.) at 150° C. for 10 minutes. 
Approximately 1000 A of chromium (Mat-Vac Technology, 
Flagler Beach, Fla.) was deposited onto the wafers using a 
DC-sputterer (601 Sputtering System, CVC Products, Roch-
ester, N.Y.). The chromium layer was patterned into 20 by 20 
arrays of 80 µm diameter dots with 150 µm center-to-center 
spacing using the lithographic process described below. 
20 
required only gentle pushing. Inspection by light and electron 
microscopy showed that more than 95% of microneedles 
within an array pierced across the stratum corneum of the 
epidermis samples. Moreover, essentially all of the micron-
eedles that penetrated the epidermis remained intact. On 
those very few which broke, only the top 5-10 µm was dam-
aged. Microneedle arrays could also be removed without 
difficulty or additional damage, as well as re-inserted into 
skin multiple times. 
To quantitatively assess the ability of microneedles to 
increase transdermal transport, calcein permeability of 
human epidermis with and without inserted microneedle 
arrays was measured. Calcein crosses skin very poorly under 
normal circumstances and therefore represents an especially 
15 difficult compound to deliver. As expected, passive perme-
ability of calcein across unaltered skin was very low, indicat-
ing that the epidermis samples were intact. 
A layer of photosensitive material (1827 photoresist, Shi- 10 
pley, Marlborough, Mass.) was deposited onto the chromium 
layer covering the silicon wafers. A standard lithographic 
mask (Telic, Santa Monica, Calif.) bearing the appropriate 
dot array pattern was positioned on top of the photoresist 
layer. The wafer and photoreist were then exposed to ultra-
violet (UV) light through the mask by means of an optical 
mask aligner (Hybralign Series 500, Optical Associates, Inc., 
Milpitas, Calif.). The exposed photoresist was removed by 
soaking the wafers in a liquid developer (354 developer, Shi-
pley, Marlborough, Mass.) leaving the desired dot array of 
photoresist on the chromium layer. Subsequently, the wafers 
were dipped into a chromium etchant (CR-75; Cyanteck Fre-
mont, Calif.), which etched the chromium that had been 
exposed during the photolithography step, leaving dot arrays 
Insertion of microneedles into skin was capable of dramati-
cally increasing permeability to calcein. When microneedles 
20 were inserted and left embedded in the skin, calcein perme-
ability was increased by more than 1000-fold. Insertion of 
microneedles for 10 s, followed by their removal, yielded an 
almost 10,000-fold increase. Finally, insertion of a micron-
eedle array for 1 h, followed by its removal, increased skin 
of chromium (covered with photoresist) on the surface of the 
silicon wafer. The photoresist still present on the chromium 
dots formed the masks needed for fabrication of the micron-
eedles, described below. 
The microneedles were fabricated using a reactive ion 
etching techniques based on the Black Silicon Method devel-
oped at the University ofTwente. The patterned wafers were 
etched in a reactive ion etcher (700 series wafer/batch Plasma 
Processing System, Plasma Therm, St. Petersburg, Fla.) with 
means for ensuring good thermal contact between the wafers 
and the underlying platen (Apiezon N, K. J. Lesker, Clairton, 
Pa.). The wafers were etched using the following gases and 
conditions: SF 6 (20 standard cubic centimeters per minute) 
and 0 2 (15 standard cubic centimeters per minute) at a pres-
sure of 150 mTorr and a power of 150 W for a run time of 
approximately 250 minutes. These conditions caused both 
deep vertical etching and slight lateral underetching. By con-
trolling the ratio of flow rates of the SF 6 and 0 2 gases used to 
form the plasma, the aspect ratio of the microneedles could be 
adjusted. The regions protected by the chromium masks 
remained and formed the microneedles. Etching was allowed 
to proceed until the masks fell off due to underetching, result-
ing in an array of sharp silicon spikes. 
EXAMPLE2 
Transdermal Transport Using Solid Microneedles 
25 permeability by about 25,000-fold. Permeabilities for skin 
with microneedles inserted and then removed are higher than 
for skin with microneedles remaining embedded probably 
because the microneedles themselves or the silicon plate sup-
porting the array may block access to the microscopic holes 
30 created in the skin. Light microscopy showed that the holes 
which remained in the skin after microneedles were removed 
were approximately 1 µm in size. 
To confirm in vitro experiments which showed that skin 
permeability can be significantly increased by microneedles, 
35 studies were conducted with human volunteers. They indi-
cated that microneedles could be easily inserted into the skin 
of the forearm or hand. Moreover, insertion of microneedle 
arrays was never reported to be painful, but sometimes elic-
ited a mild "wearing" sensation described as a weak pressure 
40 or the feeling of a piece of tape affixed to the skin. Although 
transport experiments were not performed in vivo, skin elec-
trical resistance was measured before and after microneedle 
insertion. Microneedles caused a 50-fold drop in skin resis-
tance, a drop similar to that caused by the insertion of a 
45 30-gauge "macroneedle." Inspection of the site immediately 
after microneedle insertion showed no holes visible by light 
microscopy. No erythema, edema or other reaction to micron-
eedles was observed over the hours and days which followed. 
This indicates that microneedle arrays can permeabilize skin 
50 in human subjects in a non-painful and safe manner. 
EXAMPLE3 
To determine if microfabricated microneedles could be 
used to enhance transdermal drug delivery, arrays of micron-
eedles were made using a deep plasma etching technique. 55 
Their ability to penetrate human skin without breaking was 
tested and the resulting changes in transdermal transport were 
measured. 
Fabrication of Silicon Microtubes 
Three-dimensional arrays of microtubes were fabricated 
from silicon, using deep reactive ion etching combined with a 
modified black silicon process in a conventional reactive ion 
etcher. The fabrication process is illustrated in FIGS. Sa-d. 
First, arrays of 40 µm diameter circular holes 32 were pat-
terned through photoresist 34 into a 1 µm thick Si02 layer 36 
Arrays of microneedles were fabricated having extremely 
sharp tips (radius of curvature less than 1 µm) which facilitate 60 
easy piercing into the skin, and are approximately 150 µm 
long. Because the skin surface is not flat due to dermatoglyph- on a two inch silicon wafer 38 (FIG. Sa). The wafer 38 was 
then etched using deep reactive ion etching (DRIE) (Laermer, 
et al., "Bosch Deep Silicon Etching: Improving Uniformity 
ics and hair, the full length of these microneedles will not 
penetrate the skin. All experiments were, performed at room 
temperature (23±2° C.). 
The ability of the microneedles to pierce skin without 
breaking was then tested. Insertion of the arrays into skin 
65 and Etch Rate for Advanced MEMS Applications," Micro 
Electro Mechanical Systems, Orlando, Fla., USA (Jan. 17-21, 
1999)) in an inductively coupled plasma (ICP) reactor to etch 
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deep vertical holes 40. The deep silicon etch was stopped after 
the holes 40 are approximately 200 µm deep into the silicon 
substrate 3S (FIG. Sb) and the photoresist 34 was removed. A 
second photolithography step patterned the remaining Si02 
layer 36 into circles concentric to the holes, thus leaving ring 5 
shaped oxide masks 34 surrounding the holes (FIG. Sc). The 
photoresist 34 was then removed and the wafer 3S was again 
deep silicon etched, while simultaneously the holes 40 were 
etched completely through the wafer 3S (inside the Si02 ring) 
and the silicon was etched around the Si02 ring 3S leaving a 10 
cylinder 42 (FIG. Sd). The resulting tubes were 150 µmin 
height, with an outer diameter of 80 µm, an inner diameter of 
40 µm, and a tube center-to-center spacing of300 µm. 
EXAMPLE4 15 
Micromold Fabrication of Metal Microtubes 
22 
vided a negative of the microneedles with a small diameter 
hole where the tip of the silicon needle protruded. After the 
removal of the silicon, a seed layer of Ti-Cu-Ti S4 was 
conformally sputter-deposited onto the top and sidewalls of 
the epoxy micromold S2. Following the same process 
sequence as described in Example 4, NiFe was then electro-
plated onto the seedlayerS4 (FIG. 7c). Finally, the epoxy was 
removed using an OiCHF 3 plasma, leaving a 20x20 array of 
NiFe hollow metal microneedles S4 (FIG. 7d). The micron-
eedles S4 were 150 µm in height with a base diameter of 80 
µm, a tip diameter of 10 µm, and a needle to needle spacing of 
150 µm. 
EXAMPLE 6 
Micromold Fabrication of Tapered Microneedles 
Using Laser-Formed Molds 
A micromold having tapered walls was fabricated by use of 
laser ablation techniques, as shown in FIGS. Sa-d. A laser-Hollow metal microtubes were prepared without dry sili-
con etching, using a thick, photo-defined mold of epoxy. The 
sequences are illustrated in FIGS. 6a-e. First, a thick layer of 
SU-8 epoxy 44 was spin cast onto a silicon or glass substrate 
46 that had been coated with 30 nm of titanium 4S, the 
sacrificial layer. Arrays of cylindrical holes 49 were then 
photolithographically defined through an epoxy layer 44, 
typically 150 µm thick (FIG. 6a). The sacrificial layer then 
was partially removed using a wet etching solution containing 
hydrofluoric acid and water at the bottom of the cylindrical 
holes in the SU-8 photoresist 46 (FIG. 6b). A seed layer of 
Ti/Cu/Ti (30 mn/200 mn/30 nm), 39 Was then conformally 
DC sputter-deposited onto the upper surface of the epoxy 
mold and onto the sidewalls of the cylindrical holes 49 (FIG. 
6c). As shown in FIG. 6c, the seed layer 4S was electrically 
isolated from the substrate. Subsequently, NiFe was electro-
plated onto the seed layer 4S (FIG. 6d), the epoxy 44 was 
removed from the substrate, and the surrounding epoxy 44 
was removed (FIG. 6e). The resulting microtubes are 200 µm 
in height with an outer diameter of 80 µm, an inner diameter 
of 60 µm, and a tube center-to-center spacing of 150 µm. The 
holes in the interior of the microtubes protrude through the 
base metal supporting the tubes. 
20 ablatable polymer sheet 60 such as KAPTOWM polymide 
approximately 150 microns in thickness was optionally lami-
nated to a thin (10-30 micron) metal sheet 62 such as titanium 
(FIG. Sa). A tapered hole 64 was formed in the metal/polymer 
laminate 60/62 using a laser technique such as excimer laser 
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25 ablation (FIG. Sb). The entry hole of the laser spot was on the 
metal side 62, and a through hole was made through both the 
metal sheet and the polymer film. The through hole 64 was 
tapered in combination with either defocusing or appropriate 
substrate motion to create a taper such that the wide end of the 
hole 64 (typically 40-50 microns) was on the metal side 62 
30 
and the narrow end of the hole 64 (typically 10-20 microns) 
was on the polymer 60 side. A thin layer of metal 66, e.g. 
titanium, of thickness 0.1 micron was then deposited, e.g., 
using a sputter-deposition technique, in such a way that the 
metal 66 deposited on the metal film side and coated the 
35 polymer sidewalls, but did not coat the polymer 60 side of the 
laminate (FIG. Sc). Electrodeposition of metal 6S, e.g., gold, 
to a thickness of 1-5 microns was then performed on the 
titanium-coated metal surface 66, and polymer sidewalls 
curved section of 60 next to 64. Finally, the polymer 60 was 
40 removed, using e.g. an oxygen plasma, to form the completed 
microneedles (FIG. Sd). 
Alternate polymer removal methods, such as thermal, sol-
vent, aqueous, or phodegradation followed by solvent or 
aqueous removal, are also possible ifthe polymer material is 
45 chosen appropriately (e.g., a photoresist resin). 
Amicromoldhavingtapered walls was fabricated by mold-
ing a preexisting 3-D array of microneedles, i.e. the mold-
insert, and subsequently removing the mold insert. The 
micromold was then surface plated in a manner similar to that 50 
for the microtubes described in Example 4. The fabrication 
sequence is illustrated in FIGS. 7a-7d. 
EXAMPLE 7 
Formation ofMicroneedles by Embossing 
Formation of a microneedle by embossing is shown in 
FIGS. 9a-9f A polymeric layer 70 (FIG. 9a) is embossed by 
a solid microneedle or microneedle array 72 (FIG. 9b). The 
array 72 is removed (FIG. 9c ), and the layer 70 is etched from 
the non-embossed side 74 until the embossed cavity 76 is 
exposed (FIG. 9d). A metallic layer 7S is then deposited on 
the embossed side and the sidewalls, but not on the non-
embossed side 74 (FIG. 9e). This layer 7S is optionally thick-
ened by electrodeposition of an additional metal layer SO on 
top of it (FIG. 9e ). The polymer layer 70 is then removed to 
form the microneedles 7S/SO (FIG. 9j). 
First, an array of solid silicon microneedles SO were pre-
pared as described in Henry, et al., "Micromachined Needles 
for the Transdermal Delivery of Drugs," Micro Electro 55 
Mechanical Systems, Heidelberg, Germany, Jan. 26-29, pp. 
494-498 (1998). Then, a layer of epoxy S2 (SU-8) was spin 
cast onto the microneedle array to completely blanket the 
array FIG. 7a). The epoxy S2 settled during pre-bake to create 
a planar surface above the tips of the microneedles SO. The 60 
epoxy S2 was then fully pre-baked, photolithographically 
cross-linked, and post-baked. 
Then, the upper surface of the epoxy S2 was etched away 
using an 0 2 /CHF 3 plasma until approximately 1to2 µm of the 
needle tips S4 were exposed, protruding from the epoxy S2 65 
(FIG. 7b). The silicon was then selectively removed by using 
a SF6 plasma (FIG. 7c). The remaining epoxy mold S2 pro-
EXAMPLE 8 
Transdermal Application of Hollow Microneedles 
The bore of hollow microneedles must provide fluid flow 
with minimal clogging in order to be suitable to transport 
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material, such as in transdermal drug delivery. Therefore, 
microneedles and microtubes were evaluated to determine 
their suitability for these functions. 
Hollow metal and silicon microneedles, produced as 
described in Examples 3-5, were inserted through human skin 
epidermis with no apparent clogging of the needle bores. 
Scanning electron microscopy of a hollow metal (NiFe) 
microneedle penetrating up through the underside of human 
epidermis showed the microneedle remains intact, with the 
tip free of debris. Similarly, silicon microneedles, metal 10 
microneedles, and metal microtubes were successfully 
inserted through human skin. Also, the hollow microneedles 
were shown to permit the flow of water through theft bores. 
EXAMPLE9 
Transport of Drugs Through Microneedles Inserted 
into Skin 
15 
20 
Studies were performed with solid and hollow micron-
eedles to demonstrate transport of molecules and fluids. As 
shown in Table 1, transport of a number of different com-
pounds across skin is possible using microneedles. These 
studies were performed using either solid silicon micron- 25 
eedles or using hollow silicon microneedles made by methods 
described in this patent. Transport was measured across 
human cadaver epidermis in vitro using Franz diffusion 
chambers at 37° C. using methods described in S. Henry, D. 
McAllister, M. G.AllenandM. R. Prausnitz. Microfabricated 30 
microneedles: A novel method to increase transdermal drug 
delivery. J. Phann. Sci. 87, 922-925 (1998). 
The transdermal delivery of calcein, insulin, bovine serum 
albumin and nanoparticles was measured. Delivery refers to 
the ability to transport these compounds from the stratum 35 
corneum side of the epidermis to the viable epidermis side. 
This is the direction of transport associated with delivering 
drugs into the body. Removal of calcein was also measured. 
Removal refers to the ability to transport calcein from the 
viable epidermis side of the epidermis to the stratum corneum 40 
side. This is the direction of transport associated with remov-
ing from the body compounds found in the body, such as 
glucose. 
24 
TABLE 1 
Transport of Drugs through Micro needles inserted into Skin. 
Solid needles 
No Solid needles inserted and Hollow needle 
Compound needles inserted removed inserted 
Calcein 4 x 10-3 1 x 10-2 1x10-1 
delivery 
Calcein 2 x 10-3 1 x 10-2 n.a. 
removal 
Insulin 1x10-4 1 x 10-2 n.a. 
delivery 
Bovine serum 9 x 10-4 8 x 10-3 9 x 10-2 
albumin 
delivery 
Nanoparticle n.a. 3 x 10-5 n.a. 
delivery 
** means that the transport was below the detection limit. 
n.a. means that the data are not available. 
Nanoparticles were made of latex with a diameter of approximately 100 run. 
TABLE2 
Flow rate of water through hollow silicon microneedles 
as a fllilction of applied pressure 
Pressure (psi) Flow rate (ml/min) 
1.0 16 
1.5 24 
2.0 31 
2.5 38 
3.0 45 
Publications cited herein and the material for which they 
are cited are specifically incorporated by reference. 
Those skilled in the art will recognize, or be able to ascer-
tain using no more than routine experimentation, many 
equivalents to the specific embodiments of the invention 
described herein. Such equivalents are intended to be encom-
passed by the following claims. 
We claim: 
1. A method for delivering of active agent across a biologi-
cal barrier, the method comprising the steps of: 
puncturing the biological barrier with a plurality of 
microneedles, the microneedles attached to or integrally 
formed with a substrate, wherein each of the micron-
eedles is formed of a biodegradable polymer and an 
active agent dispersed in the biodegradable polymer of 
the microneedles; 
delivering the active agent solely through biodegradation 
of the biodegradable polymer of the microneedles in the 
biological barrier. 
In all cases shown in Table 1, transport of these compounds 
across skin occurred at levels below our detection limit when 45 
no needles were inserted into the skin. Intact skin provides an 
excellent barrier to transport of these compounds. In all cases 
examined, when solid microneedles were inserted into the 
skin and left in place, large skin permeabilities were mea-
sured, indicating that the microneedles had created pathways 50 
for transport across the skin. Furthermore, in all cases, when 
solid microneedles were inserted into the skin and then 
removed, even greater skin permeabilities resulted. Finally, 
when hollow microneedles were inserted into the skin and left 2. The method of claim 1, wherein the biodegradable poly-
55 mer comprises a plurality of biodegradable polymers. in place, still greater skin permeabilities resulted for those 
compounds tested. These studies show that microneedles can 
dramatically increase skin permeability and can thereby 
increase transport of a number of different compounds across 
the skin. It also shows that when solid microneedles are used, 
3. The method of claim 2, wherein the biodegradable poly-
mer comprises at least one of polylactides, polyglycolides, 
polylactide-co-glycolide, copolymers of polyethylene gly-
col, polyanhydrides, poly( ortho )esters, polyurethanes, poly 
a preferred embodiment involves inserting and then removing 
microneedles, rather than leaving them in place. It also shows 
that using hollow microneedles are a preferred embodiment 
over the use of solid microneedles. 
60 (butric acid), poly(valeric acid), and poly(lactide-co-capro-
lactone ). 
In Table 2, the flow rate of water through hollow silicon 
microneedles is shown as a function of applied pressure. 65 
These data demonstrate that significant flow rates of water 
through microneedles can be achieved at modest pressures. 
4. The method of claim 1, wherein the biodegradable poly-
mer comprises a biodegradable polymer and a non-biode-
gradable polymer. 
5. The method of claim 1, wherein the biodegradation 
occurs by way of chemical breakdown of the biodegradable 
polymer. 
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6. The method of claim 1, wherein the biodegradation 
occurs by way of biodissolution of the biodegradable poly-
mer. 
7. The method of claim 1, wherein the microneedles are 
between 1 µm and 1 mm long, inclusive. 
8. The method of claim 1, wherein the microneedles are 
between 10 µm and 500 µm long, inclusive. 
9. The method of claim 1, wherein the microneedles are 
between 30 µm and 200 µm long, inclusive. 
10. The method of claim 1, wherein the microneedles have 
10 
a cross-sectional dimension between 10 nm and 1 mm, inclu-
sive. 
11. The method of claim 1, wherein the microneedles have 
a cross-sectional dimension between 1 µm and 200 µm, inclu-
sive. 
12. The method of claim 1, wherein the microneedles have 15 
a cross-sectional dimension between 10 µm and 100 µm, 
inclusive. 
13. The method of claim 1, wherein the microneedles have 
a circular cross section with an outer diameter between 10 µm 
and 100 µm, inclusive. 
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14. The method of claim 1, wherein the substrate comprises 
a flexible material. 
15. The method of claim 1, wherein the active agent is 
dispersed throughout the biodegradable polymer. 
16. The method of claim 1, wherein the active agent is a 
drug. 
17. The method of claim 16, wherein the drug comprises at 
least one of a protein, an enzyme, a polysaccharide, a poly-
nucleotide, an organic compound, and an inorganic com-
pound. 
18. The method of claim 1, wherein at least one of the 
microneedles comprises a break site to remove the at least one 
of the microneedles from the substrate. 
19. The method of claim 18, wherein the break site com-
prises a notch in the at least one of the microneedles. 
20. The method of claim 18, wherein the break site is 
located adjacent the tip of the microneedles. 
* * * * * 
